2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Abstract

Objective. To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).Methods. We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/ outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate the quality of the evidence. A voting panel, including rheumatologists, dermatologists, other health professionals, and patients, achieved consensus on the direction and the strength of the recommendations.Results. The guideline covers the management of active PsA in patients who are treatment-naive and those who continue to have active PsA despite treatment, and addresses the use of oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitors (IL-12/23i), IL-17 inhibitors, CTLA4-Ig (abatacept), and a JAK inhibitor (tofacitinib). We also developed recommendations for psoriatic spondylitis, predominant enthesitis, and treatment in the presence of concomitant inflammatory bowel disease, diabetes, or serious infections. We formulated recommendations for a treat-to-target strategy, vaccinations, and nonpharmacologic therapies. Six percent of the recommendations were strong and 94% conditional, indicating the importance of active discussion between the health care provider and the patient to choose the optimal treatment.Conclusion. The 2018 ACR/NPF PsA guideline serves as a tool for health care providers and patients in the selection of appropriate therapy in common clinical scenarios. Best treatment decisions consider each individual patient situation. The guideline is not meant to be proscriptive and should not be used to limit treatment options for patients with PsA. Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intendedto provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the health care provider in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions. These recommendations cannot adequately convey all uncertainties and nuances of patient care.The American College of Rheumatology...

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

“…These are the first 5-year findings reported for secukinumab in PsA, and the data add to the growing body of evidence supporting the use of IL-17 inhibitors for the treatment of PsA as recognized in the guidelines from the EULAR (8), GRAPPA (11), and recently the ACR/National Psoriasis Foundation (NPF) (19). The patient retention rates in this study were high, with over 80% of patients who entered the extension study completing the full 5-year treatment period.…”

Singapore chapter of rheumatologists' updated consensus statement on the eligibility for government subsidization of biologic and targeted therapy for the treatment of psoriatic arthritis

“…The most recent 2018 ACR guideline was not published at the time of our review and consensus process. The focus of this guideline was on evidence‐based treatment in PsA with all biologic drug classes endorsed for use as first and alternate lines of therapy and recommended based on specific disease characteristics …”

Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East

“…Guidelines published by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)/National Psoriasis Foundation (NPF) provide recommendations for the management of PsA [35,36]. A limitation of the EULAR guidelines is that they are focused on the management of the musculoskeletal manifestations of PsA, while the management of psoriatic skin disease is not addressed [37].…”

“…Clinical guidelines for PsA jointly developed by ACR/NPF were recently published and are the first to include new therapeutic agents for the treatment of PsA, such as inhibitors of interleukin (IL)-17 and Janus kinase. These guidelines provide treatment recommendations for the management of both musculoskeletal disease and severe psoriasis [36].…”